Skip to main content
Terug
Watch Compare

Hoth Therapeutics, Inc.

Datakwaliteit: 83%
HOTH
NASDAQ Manufacturing Chemicals
€ 0,50
▼ € 0,02 (-3,07%)
Marktkapitalisatie: 10,32 M
Prijs
€ 0,54
Marktkapitalisatie
10,32 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Negative free cash flow of -9,80 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-138,74%
Onder sectorgemiddelde (-54,01%)
ROIC-108,66%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio8,81
Interest CoverageN/A

Waardering

PE (TTM)
-0,83
Boven sectorgemiddelde (-1,49)
P/B Ratio1,25
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1385 peers)
Metriek Aandeel Sector Mediaan
P/E -0,8 -1,5
P/B 1,3 1,6
ROE % -138,7 -54,0
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

Koersdoel Analisten

1 analist
Buy
Huidig
€ 0,50
+900.6%
Koersdoel
€ 5,00
€ 5,00
€ 5,00
€ 5,00
Vooruitzicht
Forward WPA -€ 0,70
Omzet Sch. 0,0

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2027 -€ 0,70
-€ 0,70 – -€ 0,70
 0,0 1
FY2026 -€ 0,59
-€ 0,59 – -€ 0,59
 0,0 1

Winstverassingen

Laatste 4 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q42025 -€ 0,10 -€ 0,16 -60,0%
Q32025 -€ 0,07 -€ 0,30 -328,6%
Q22025 -€ 0,14 -€ 0,17 -21,4%
Q12025 -€ 0,34 -€ 0,27 +20,6%

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -12,47 M
ROE -138,74% ROA -128,87%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -9,80 M
ROIC -108,66% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 8,81
Interest Coverage N/A Asset Turnover N/A
Working Capital 7,91 M Tangible Book Value 8,23 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,83 Forward P/E N/A
P/B Ratio 1,25 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -94,99%
Market Cap 10,32 M Enterprise Value 2,47 M
Per Share
EPS (Diluted TTM) -0,90 Revenue / Share N/A
FCF / Share -0,51 OCF / Share -0,51
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 78,62%
SBC-Adj. FCF -11,28 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -12,47 M -8,19 M -7,85 M -11,37 M -14,31 M
EPS (Diluted) -0,90 -1,28 -2,30 -8,79 —
Gross Profit — — — — —
Operating Income -12,36 M -8,22 M -7,69 M -11,07 M -14,10 M
EBITDA — — — — —
R&D Expenses 5,95 M 3,25 M 3,48 M 4,84 M 7,35 M
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense — — — — —
Income Tax — — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 7,60 M 7,71 M 9,52 M 6,76 M 10,99 M
Total Liabilities 1,45 M 833.906,0 704.983,0 1,64 M 1,10 M
Shareholders' Equity 6,15 M 6,88 M 8,82 M 5,12 M 9,88 M
Total Debt — — — — —
Cash & Equivalents 6,25 M 7,04 M 9,29 M 6,43 M 8,54 M
Current Assets 6,86 M 7,64 M 9,43 M 6,73 M 10,58 M
Current Liabilities 1,45 M 831.197,0 678.657,0 1,39 M 867.787,0